Sublingual Misoprostol With or Without Intravenous Tranexamic Acid During Hemorrhagic Cesarean Section

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: Female

Summary

Purpose to evaluates the effects of sublingual misoprostol with or without intravenous tranexamic acid (TA) on reducing post-partum hemorrhage during and after hemorrhagic cesarean section.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: Misoprostol; Tranexamic Acid

Criteria

Inclusion Criteria:

• women who undergone elective cesarean section (C.S) and exposed to intraoperative bleeding about 500 ml diagnosed by visual analog estimation due to atonic uterus

• age between 18 and 45 years, gestational age of 37-40 weeks, singleton pregnancy, CS with inferior segment incision, and spinal anesthesia.

Exclusion Criteria:

• having an underlying disease (heart, liver, kidney, pulmonary, etc.),

• eclampsia and severe preeclampsia

• allergy to TA (such as known allergy or thromboembolic event during pregnancy) and misoprostol

• coagulation disorders

• refuse or unable to consent